Clinical Evaluation of Nelarabine (506U78)in Japanese Patients With Leukemia or Lymphoma

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GlaxoSmithKline
ClinicalTrials.gov Identifier:
NCT00406757
First received: November 30, 2006
Last updated: May 31, 2012
Last verified: May 2011
  Purpose

In Japan, patients with relapsed or refractory T-ALL/T-LBL represent an extremely small patient population. While the small number of patients presents a practical limitation to the size of a clinical trial, patients whose disease has not responded to or has relapsed after treatment with multiple prior chemotherapy regimens have no accepted standard therapies available. Japanese leukemia experts have expressed interest in evaluating 506U78 in Japanese patients with relapsed or refractory T-ALL/T-LBL. In order to obtain safety, tolerability, and pharmacokinetic data of 506U78 in Japanese patients, this study is designed to maximize the contribution of each available patient.


Condition Intervention Phase
Leukaemia, Lymphoblastic, Acute and Lymphoma, Lymphoblastic
Lymphoblastic Lymphoma
Acute Lymphoblastic Leukemia
Drug: Nelarabine injection 400mg/m2
Drug: Nelarabine injection 650mg/m2
Drug: Nelarabine injection 1000mg/m2
Drug: Nelarabine injection 1500mg/m2
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Evaluation of 506U78 in Japanese Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma.

Resource links provided by NLM:


Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Adverse events, changes from baseline in physical examination and clinical laboratory parameters12-lead ECGAssessment of pharmacokinetic endpoints of 506U78, ara-G and intracellular ara-GTP concentration. [ Time Frame: Day 21 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Evaluation of response (e.g., CR, CR*) in patients with bone marrow involvement. [ Time Frame: Day 21 ] [ Designated as safety issue: No ]

Enrollment: 13
Study Start Date: August 2006
Study Completion Date: July 2009
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Pediatric Arm 1

Cycle 1: Nelarabine 400mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.

Cycle 2 and subsequent Cycles: Nelarabine 650mg2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.

Drug: Nelarabine injection 400mg/m2

Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.

Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5.

Active Comparator: Pediatric Arm 2
Cycle 1 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to Day 5 followed by 16 days of off-dose.
Drug: Nelarabine injection 650mg/m2
Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
Active Comparator: Adult Arm 1

Cycle 1: Nelarabine 1000mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.

Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.

Drug: Nelarabine injection 1000mg/m2

Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.

Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.

Active Comparator: Adult Arm 2
Cycle 1 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once daily on Days 1, 3 and 5 followed by 16 days of off-dose.
Drug: Nelarabine injection 1500mg/m2
Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
Active Comparator: Pediatric Arm 3
Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
Drug: Nelarabine injection 650mg/m2
Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.

  Eligibility

Ages Eligible for Study:   up to 64 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologic or cytogenetic documented diagnosis of T-ALL or T-LBL.
  • Disease that is refractory to at least one prior chemotherapy regimen, or has relapsed following complete remission to at least one prior chemotherapy regimen.
  • At least 4 weeks since the last dose of prior last chemotherapy, or radiotherapy before beginning treatment with 506U78 (2 weeks is permitted if growth of blast cells is significant).
  • Adequate function of other organ systems as measured as follows.Serum creatinine is less than 1.5 times of upper limit of normal and estimated creatinine clearance >=50 mL/min. Hepatic transaminases (SGPT and SGOT) <=3 x upper limit of normal, bilirubin is less than 1.5 times of upper limit of normal(<=5 x upper limit of normal if it is related by T-ALL or T-LBL).
  • Adequate performance status (ECOG-PS<=2).
  • Capable of giving informed consent which includes compliance with the requirements and restrictions listed in the consent form.
  • Patient is willing to accept hospitalization during the blood sampling for pharmacokinetic measurement (i.e., Cohort 1: for pharmacokinetic sample collection during both cycle 1 and 2; and Cohort 2: for pharmacokinetic sample collection during cycle 1).
  • Female subjects who are of child-bearing potential must have a negative pregnancy test at the Screening Visit and agree to utilize contraceptive methods during participation in the study and for at least six months following the last dose of 506U78 Injection. Female subjects may be defined as of non-child-bearing potential if they are physiologically incapable of becoming pregnant, including any female who is post-menopausal. For purposes of this study, postmenopausal is defined as one year without menses.

Exclusion Criteria:

  • Active infection at time of treatment.
  • Concurrent disease or condition that would make the subject inappropriate for study participation.
  • Receiving any other anticancer agents or enrolled on any investigational study during the course of the study.
  • Patients must have recovered to Grade I or less toxicity of all previous chemotherapy prior to treatment.
  • History of seizure disorder within one year prior to the date of informed consent.
  • Pregnancy (as demonstrated by a positive pregnancy test at pre-study/screening) or breastfeeding. Fertile women and men must practice adequate contraception throughout the study and at least 6 month after the last dose of study drug.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00406757

Locations
Japan
GSK Investigational Site
Aichi, Japan, 460-0001
GSK Investigational Site
Tokyo, Japan, 104-0045
GSK Investigational Site
Tokyo, Japan, 104-8560
Sponsors and Collaborators
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

No publications provided

Responsible Party: GlaxoSmithKline
ClinicalTrials.gov Identifier: NCT00406757     History of Changes
Other Study ID Numbers: PGA105446
Study First Received: November 30, 2006
Last Updated: May 31, 2012
Health Authority: Japan: Ministry of Health, Labor and Welfare

Keywords provided by GlaxoSmithKline:
T-cell
T-ALL
T-LBL
506U78
ara-G
ara-GTP
Lymphoma
Leukemia

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma
Lymphoma, Non-Hodgkin
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases

ClinicalTrials.gov processed this record on April 17, 2014